REBOOT‐CNIC2018.

Study name	TREatment With Beta‐blockers After myOcardial Infarction withOut Reduced Ejection fracTion
Methods	Randomised, open‐label, blinded endpoint clinical trial
Participants	Patients being discharged after an acute MI, with or without ST‐segment elevation, and with left ventricular ejection fraction > 40%, without history of heart failure (HF) before study inclusion
Interventions	Experimental: beta‐blocker therapy: atenolol, bisoprolol, carvedilol, metoprolol, nebivolol Control: no beta‐blocker therapy
Outcomes	Primary outcome • Composite of "all‐cause death, nonfatal reinfarction, or heart failure hospitalisation" Secondary outcomes • Incidence rate of individual components of the primary outcome • Incidence rate of cardiac mortality • Incidence rate of cardiac arrhythmias • Incidence of subsequent revascularisations • Incidence of ICD (including CRT) insertion
Starting date	23 July 2018
Contact information	Borja Ibañez, MD, PhD, FESC; bibanez@cnic.es
Notes	Estimated primary completion date: 15 November 2024 NCT number: NCT03596385